📬 GYN Oncology Intelligence Digest — Week 2026-W42

ASCO's new recurrent ovarian cancer guideline algorithm and the single-arm NANT trial of neoadjuvant niraparib dominated gynecologic oncology discussion, alongside first-in-human data for the FRα ADC sofetabart mipitecan and the published KEYLYNK-001 readout.

⚡ TL;DR

📄 Publications

Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study. — Phase 1 enrolled 105 patients with high-grade ovarian cancer, majority platinum resistant, treated at 2, 3, 4 or 6 mg/kg every 21 days; median prior treatments 5.0 and 19 (18.1%) had prior mirvetuximab
Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial. — Single-arm phase 2 trial at six Chinese tertiary hospitals enrolled 67 patients with treatment-naive FIGO stage III-IV HRD-positive high-grade serous or endometrioid ovarian cancer unsuitable for complete primary debulking, given two 28-day cycles of niraparib at 200 mg or 300 mg

🐦 Twitter / 🦋 Bluesky

New ASCO 2026 recurrent ovarian cancer guideline: FRα-high mirvetuximab gets a strong recommendation, trabectedin-PLD and routine secondary cytoreduction are out — For platinum-sensitive recurrence the guideline keeps a platinum doublet backbone of carboplatin plus PLD, paclitaxel or gemcitabine, with optional bevacizumab followed by maintenance bevacizumab
Update: KEYLYNK-001 lands in The Lancet Oncology and the conversation narrows to a PFS win with no overall survival benefit — In phase III KEYLYNK-001, pembrolizumab plus chemotherapy followed by pembrolizumab/olaparib improved PFS in newly diagnosed BRCA-nonmutated advanced ovarian cancer, but overall survival was not improved
FRα antibody-drug conjugates after mirvetuximab: sofetabart mipitecan and rinatabart sesutecan report activity independent of FRα level — Sofetabart mipitecan is an Fc-silent FRα-specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor
NANT: chemotherapy-free neoadjuvant niraparib gets 63% response and 80% R0 in HRD-positive ovarian cancer, but attrition and single-arm design keep it investigational — Sixty-seven patients with unresectable HRD-positive advanced ovarian cancer received neoadjuvant niraparib monotherapy for 8 weeks
ESMO 2026 gyn agenda sharpens: TroFuse-005 in endometrial cancer and the DENALI azenosertib OS readout in platinum-resistant disease — TroFuse-005 tests sac-TMT, a TROP2 ADC, after platinum and immunotherapy in endometrial cancer at the Presidential Symposium on Oct 26, with OS and PFS met, alongside a phase 2 of sac-TMT plus pembrolizumab in post-platinum pMMR disease

Full details below ↓

📄 What's Being Published

Manuscripts:

Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study. — Ray-Coquard I et al., Ann Oncol

The phase 1 study enrolled 105 patients with high-grade ovarian cancer, the majority platinum resistant, treated at 2, 3, 4 or 6 mg/kg every 21 days. The median number of prior treatments was 5.0, and 19 (18.1%) patients had prior mirvetuximab. Overall response rate was 50.5% (95% CI 40.5, 60.4) overall, 58.8% at 3 mg/kg, 44.4% for FRα <75%, 56.5% for FRα ≥75% and 57.9% after prior mirvetuximab. Median PFS was 8.1 months (95% CI 6.4, 8.5) at a median follow-up of 12.9 months. The most common TEAEs were nausea (64.8%), fatigue (56.2%) and anemia (47.6%), with no keratopathies or grade ≥3 neuropathy. Grade ≥3 treatment-related TEAEs occurred in 35.3% at 3 mg/kg and 56.4% at 4 mg/kg, and 11 patients (10.5%) discontinued for TEAEs.

Clinical bottom line: Sofetabart mipitecan is an investigational FRα ADC that showed activity irrespective of FRα expression level or prior mirvetuximab, without keratopathy. These data support taking 3 mg/kg into the phase 3 FRAmework-01 trial. It changes nothing in practice today, but it is the FRα agent to watch for patients who have already failed mirvetuximab.

Read full article →

🔗 Also discussed on social media →

Farletuzumab ecteribulin, a folate receptor alpha (FRα) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study. — Wenham Robert M et al., Gynecol Oncol

The study enrolled eighty-nine patients (median age 67.0 years). Prior treatment was extensive: 88.7% of ovarian and 50.0% of endometrial cancer patients had received ≥2 prior regimens. ILD/pneumonitis occurred in 40% of patients in Dose-Escalation (n = 25), prompting body surface area-based dosing. In Dose-Confirmation (n = 24), ILD/pneumonitis occurred in 33.3% of patients; all events at 25 mg/m2 were grade 1/2, and the 33 mg/m2 dose was discontinued. Patients receiving 8 mg/m2 on D1/D8/D15 had no ILD/pneumonitis and more responses, though subgroups were small.

Clinical bottom line: Farletuzumab ecteribulin remains an investigational FRα ADC whose development depends on controlling a high rate of interstitial lung disease. Fractionated dosing is the current mitigation strategy, and there are no practice implications yet.

Read full article →

Platinum resistant ovarian cancer - No longer a graveyard for drug development. — Tewari Krishnansu S et al., Gynecol Oncol

The review states that platinum-resistant and refractory ovarian cancer is no longer regarded as a homogeneous entity now that targeted therapies have been tested in randomized trials. Over the past decade, five novel therapies spanning anti-angiogenesis, antibody-drug conjugates, checkpoint inhibition and glucocorticoid receptor blockade have become available, several of which confer a survival benefit. The authors identify adverse event mitigation and the role of biomarkers and their assays as issues to clarify.

Clinical bottom line: This review reframes platinum-resistant ovarian cancer as a set of biomarker-defined subpopulations rather than a single dead-end diagnosis. It is a useful citation for clinicians arguing for FRα and other biomarker testing at the time of resistance.

Read full article →

Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial. — Liu Dan et al., Lancet Oncol

The trial enrolled 67 patients with treatment-naive FIGO stage III-IV HRD-positive disease unsuitable for complete primary debulking, who received two 28-day cycles of niraparib at 200 mg or 300 mg. Among 48 response-evaluable patients, 30 responded (ORR 63%, 95% CI 47-76). Among 40 operated patients, 32 achieved R0 resection (80%, 95% CI 64-91). The most common grade 3-4 treatment-related adverse events were thrombocytopenia in 32 (48%), leukopenia in 13 (19%), anaemia in 12 (18%) and neutropenia in nine (13%). Serious adverse events occurred in 19 (28%) patients, with no treatment-related deaths, at a median follow-up of 37.7 months.

Clinical bottom line: Chemotherapy-free neoadjuvant niraparib produced responses and R0 resections in HRD-positive disease. This single-arm study does not displace platinum-taxane neoadjuvant chemotherapy, and the authors themselves call the strategy investigational pending randomised comparison.

Read full article →

🔗 Also discussed on social media →

PARAGON-II cohort C: a phase II basket study of letrozole plus ribociclib in hormone receptor-positive, platinum-resistant, high-grade epithelial ovarian cancer. — Lee Chee Khoon et al., Int J Gynecol Cancer

Thirty-two heavily pretreated participants were enrolled: 56% had ≥3 prior lines, 69% prior bevacizumab and 25% prior PARP inhibitors. Among 25 participants with measurable disease, ORR was 4.0% (95% CI 0.1 to 20.0; 1 partial response). In 30 evaluable participants, the 12-week disease control rate was 27.0%, median PFS was 1.9 months and the 6-month PFS rate was 16.0%. Grade ≥3 toxicities were mainly hematologic.

Clinical bottom line: Letrozole plus ribociclib should not be pursued in hormone receptor-positive, PIK3CA wild-type platinum-resistant ovarian cancer. The response rate was 4%, and the authors explicitly do not support further evaluation of the combination.

Read full article →

Early experience with mirvetuximab soravtansine in the treatment of recurrent low- grade serous ovarian carcinoma. — Tahan Elio et al., Int J Gynecol Cancer

This retrospective MD Anderson series included 12 patients with a median of 4 prior lines; 83.3% of tumors had high FRα expression (≥75% staining). Best responses were partial response in 4 (33.3%), stable disease in 7 (58.33%) and progressive disease in 1 (8.33%), for a disease control rate of 91.67%. Median duration of response was 8.37 months, and median PFS was not reached. Toxicities led to dose modifications in 58.33% of cases and discontinuation in 25% of patients.

Clinical bottom line: This 12-patient retrospective series supports trying mirvetuximab in heavily pretreated FRα-high recurrent low-grade serous ovarian carcinoma, a subtype excluded from the registrational trials. The small size and 25% discontinuation rate mean it should guide case-by-case decisions rather than standard practice.

Read full article →

🗂 Every paper considered this week, including the ones that didn’t make it →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

New ASCO 2026 recurrent ovarian cancer guideline: FRα-high mirvetuximab gets a strong recommendation, trabectedin-PLD and routine secondary cytoreduction are out

The new ASCO 2026 guideline keeps a platinum doublet backbone (carboplatin plus PLD, paclitaxel or gemcitabine, with optional bevacizumab and maintenance) for platinum-sensitive recurrence and states not to add trabectedin to PLD. In platinum-resistant or refractory disease, mirvetuximab soravtansine is a strong recommendation for FRα-high tumors, which requires FRα testing. Secondary cytoreduction is not routinely recommended, and HIPEC evidence remains insufficient, even as clinicians call the binary platinum "line in the sand" outdated. The tension is a separate 152-patient, 31-center study linking secondary cytoreduction in recurrent low-grade serous disease to longer survival (adjusted HR 0.28; p<0.001), with complete resection in 92%.

Discussed by: @OncoAlert, @ovarcome, @jgo_journal, @PeerView

→ View representative tweet

Sources cited: Efficacy of secondary cytoreductive surgery for relapsed ovarian low-grade serous carcino… (Journal of Gynecologic Oncology, 2026)

Update: KEYLYNK-001 lands in The Lancet Oncology and the conversation narrows to a PFS win with no overall survival benefit

In phase III KEYLYNK-001, reported by Ignace Vergote in The Lancet Oncology, pembrolizumab plus chemotherapy followed by pembrolizumab/olaparib improved PFS in newly diagnosed BRCA-nonmutated advanced ovarian cancer, but overall survival was not improved. The same week, clinicians debated changing concepts of platinum-sensitive relapse, the role of antibody-drug conjugates and therapeutic sequencing. The open question is whether a PFS-only gain earns pembrolizumab a place in any frontline ovarian regimen.

Discussed by: @ASCOPost, @myesmo.bsky.social, @ovarcome

→ View representative tweet

Sources cited: The ASCO Post

FRα antibody-drug conjugates after mirvetuximab: sofetabart mipitecan and rinatabart sesutecan report activity independent of FRα level

Sofetabart mipitecan, an Fc-silent FRα antibody linked to exatecan, produced responses overall and after prior mirvetuximab without keratopathies or grade ≥3 neuropathy. Grade ≥3 treatment-related toxicity rose with dose. Rinatabart sesutecan likewise showed efficacy regardless of FRα status in heavily pretreated platinum-resistant disease, though clinicians note there is still no answer for ADC after ADC. The debate is whether FRα immunohistochemistry stays a gating biomarker or becomes purely a label requirement for mirvetuximab.

Key numbers: Sofe-M ORR 50.5% (95% CI 40.5, 60.4) · ORR after prior MIRV 57.9% · Median PFS 8.1 mo · Grade ≥3 TRAEs 35.3% (3 mg/kg) vs 56.4% (4 mg/kg) · Rina-S 5 complete responses

Discussed by: @phsiao4, @DrBarbiOnc, @XainzaP

→ View representative tweet

Sources cited: Elsevier · Targeted Oncology · Cancer Network

NANT: chemotherapy-free neoadjuvant niraparib gets 63% response and 80% R0 in HRD-positive ovarian cancer, but attrition and single-arm design keep it investigational

Neoadjuvant niraparib monotherapy given to patients with unresectable HRD-positive disease produced responses in most evaluable patients and R0 resection in most of those operated, with higher activity in BRCA-mutated tumors. Thrombocytopenia was the dominant toxicity, and substantial attrition before response assessment weakens the signal. Both commentators and the authors call the strategy investigational, requiring randomised comparison with platinum-taxane chemotherapy. Whether a chemotherapy-free window is defensible outside a trial, even in BRCA-mutated disease, remains contested.

Key numbers: ORR 63% (30/48) · R0 80% (32/40 operated) · BRCA-mutated ORR 77% · Grade ≥3 thrombocytopenia 48% · Discontinued before response assessment 28%

Discussed by: @OncoAlert, @VCCLibrary, @vcclibrary.bsky.social

→ View representative tweet

Sources cited: Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-p… (Lancet Oncol)

ESMO 2026 gyn agenda sharpens: TroFuse-005 in endometrial cancer and the DENALI azenosertib OS readout in platinum-resistant disease

TroFuse-005, testing the TROP2 ADC sac-TMT after platinum and immunotherapy in endometrial cancer, is slated for the Presidential Symposium on Oct 26 with OS and PFS met, alongside a phase 2 of sac-TMT plus pembrolizumab in post-platinum pMMR disease. In platinum-resistant ovarian cancer, attention is on DENALI with the WEE1 inhibitor azenosertib (OS, Oct 23), with phase 3 ASPENOVA in cyclin E1-positive disease behind it and REJOICE-Ovarian02 also on the agenda. Clinicians also flagged the absence of cervical cancer prevention abstracts and asked whether a TROP2 ADC becomes the default second-line endometrial option.

Discussed by: @DrBarbiOnc, @DrYukselUrun, @OncUpdates

→ View representative tweet

🔥 Top Ranked Tweets

Sushil @Sushilberiwal

ESMO 2026 cervical cancer guidelines
The INTERLACE is not positioned as routine intensification . It may be considered particularly when access to modern radiotherapy and high-quality IGBT not available @AmericanBrachy @ARRO_org @ASTRO_org @ACROsident @KamravaMD

🔖 2 ❤️ 14 🔁 5 👁 942